https://www.live-feeds.com/feed/novo-defends-diversification-push-as-ceo-eyes-deals-beyond-obesityContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novo-defends-diversification-push-as-ceo-eyes-deals-beyond-obesityhttps://www.live-feeds.com/feed/novo-defends-diversification-push-as-ceo-eyes-deals-beyond-obesity#u83109Fri, 25 Sep 2026 00:00:40 +0000Novo Nordisk CEO Mike Doustdar aims to launch more than five blockbuster drugs by 2030, signaling a push for mergers and acquisitions to expand beyond obesity treatments. Despite these ambitions and new plans for direct-to-consumer work, the company's stock has fallen as investors express disappointment over a lack of specific turnaround details. Doustdar acknowledges the need to rebuild investor confidence while addressing the upcoming patent expiration of Ozempic, which he described as the elephant in the room.Why it mattersThe company relies heavily on its GLP-1 weight-loss portfolio,